Steven Michael Lutz Net Worth

The estimated Net Worth of Steven Michael Lutz is at least $2.83 Million dollars as of 16 December 2010. Steven Lutz owns over 65,000 units of Cortexyme Inc stock worth over $511,579 and over the last 16 years Steven sold CRTX stock worth over $2,316,300.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Steven Lutz CRTX stock SEC Form 4 insiders trading

Steven has made over 2 trades of the Cortexyme Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently Steven sold 65,000 units of CRTX stock worth $391,300 on 16 December 2010.

The largest trade Steven's ever made was selling 350,000 units of Cortexyme Inc stock on 28 July 2009 worth over $1,925,000. On average, Steven trades about 69,167 units every 84 days since 2008. As of 16 December 2010 Steven still owns at least 262,348 units of Cortexyme Inc stock.

You can see the complete history of Steven Lutz stock trades at the bottom of the page.

What's Steven Lutz's mailing address?

Steven's mailing address filed with the SEC is C/O CORNERSTONE THERAPEUTICS INC., 2000 REGENCY PARKWAY SUITE 255, CARY, NC, 27518.

Insiders trading at Cortexyme Inc

Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi, and Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.

What does Cortexyme Inc do?

Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.

Complete history of Steven Lutz stock trades at Cortexyme Inc

Cortexyme Inc executives and stock owners

Cortexyme Inc executives and other stock owners filed with the SEC include:

• Michael Detke,
  Chief Medical Officer
• Margaret Mcloughlin,
  Independent Director
• Casey C. Lynch,
  Co-Founder, Chairman, Pres & CEO
• Christopher Senner,
  Independent Director
• Dr. Michael J. Detke M.D., Ph.D.,
  Chief Medical Officer
• Dr. Leslie J. Holsinger Ph.D.,
  Exec. VP of R&D
• Casey Lynch,
  Chairman of the Board, President, Chief Executive Officer, Co-Founder
• Christopher P. Lowe M.B.A.,
  COO, CFO & Treasurer
• Caryn Gordon McDowell,
  Chief Legal & Admin. Officer and Corp. Sec.
• Stephen Dominy,
  Co-Founder, Chief Scientific Officer, Director
• Una Ryan,
  Lead Independent Director
• Kevin Young,
  Independent Director
• Christopher Lowe,
  Chief Financial Officer, Treasurer
• David Lamond,
  Independent Director
• Dr. Stephen S. Dominy,
  Co-Founder, Chief Scientific Officer & Director
• Caryn McDowell,
  Chief Legal and Administrative Officer, Corporate Secretary
• Leslie Holsinger,
  Executive Vice President - Preclinical Development
• Dr. Karen L. Smith L.L.M, L.L.M., M.B.A., M.D., PH.D.,
  Chief Medical Officer
• Brendan Hannah M.B.A.,
  Chief Bus. Officer
• Dr. Dirk Thye M.D.,
  CEO & Director
• Mary Ellen Sillivos,
  VP of HR
• Stacy Roughan,
  VP of Corp. Communications & IR
• Ted Monohon,
  VP of Fin. & Chief Accounting Officer
• Ansbert Gadicke,
  
• James B Tananbaum,
  Director
• Christopher T Phd Walsh,
  Director
• Richard W Dugan,
  Director
• M Cory Zwerling,
  Director
• Luke Evnin,
  
• Michael Steinmetz,
  
• Kurt Wheeler,
  
• Nicholas Galakatos,
  Director
• Bioventures Ii Qp Lpmpm Bio...,
  
• Dana Charles Hilt,
  SVP of Clinical Develop. & CMO
• Philip S Low,
  Director
• Marwan Sabbagh,
  Director
• Brendan Hannah,
  Chief Business Officer
• Dirk Thye,
  Chief Executive Officer
• Karen L. Smith,
  Chief Medical Officer
• Laura Shawver,
  Director
• Michael Thomas Heffernan,
  Director
• Andreas Maetzel,
  VP, Clinical and Regulatory
• Robert Stephan,
  Director
• Alan Roberts,
  VP, Scientific Affairs
• Craig A Collard,
  President and CEO
• James A Harper,
  Director
• Ira Duarte,
  Principal Accounting Officer
• Alastair Stuart Mcewan,
  Director
• Farmaceutici Sp A Chiesi,
  10% owner
• Christopher George Codeanne,
  Director
• Joshua B Franklin,
  VP, Sales and Marketing
• Marco Vecchia,
  Director
• Kenneth Mc Bean,
  President
• Anton Giorgio Failla,
  Director
• Michael David Enright,
  Director
• Ventures, Inc.Takeda Pharma...,
  
• Paul D Rubin,
  President and CEO
• Inc Pfizer Ventures (Us) Ll...,
  
• Pierre Lamond Christine Lamond,
  
• Walter Newman,
  Chief Scientific Officer/VP RD
• Howland Shaw Warren,
  Director
• Frederick Finnegan,
  VP of Sales and Marketing
• Robert H Zeiger,
  Director
• Technology Ventures Vii Lp ...,
  
• Christopher Mirabelli,
  Director
• Ventures Vi Lphealthcare Pa...,
  
• Jean George,
  Director
• Ventures, Inc. Med Immune,
  10% owner
• Bioventures Iii Qp Lpmpm Bi...,
  
• Jean Advanced Technology Ve...,
  
• Frank E Thomas,
  CFO, VP Finance and Treasurer
• & Johnson Johnson & Johnson...,
  
• Alessandro Chiesi,
  Director
• Vincent T. Morgus,
  EVP, Finance and CFO
• Brian Dickson,
  Chief Medical Officer
• Steven Michael Lutz,
  Executive Vice President
• David Price,
  Chief Financial Officer
• Bio Pharma Holdings, Ltd. C...,
  10% owner
• Scott B Townsend,
  VP OF LEGAL AFFAIRS AND SEC.
• Jeffrey E Young,
  VP FINANCE, CAO AND TREASURER
• Trevor Phillips,
  COO, VP of Operations and Sec.
• George Arthur Esgro,
  Vice President Sales
• Chenyqua Michele Baldwin,
  Vice President Finance
• Thomas Patrick Kelly,
  CFO & SVP Finance & Corp. Dev,
• Capital Group, Llc Boeding ...,
  
• Kristen Gafric,
  SVP, Legal & Administration
• Inc Pfizer Strategic Invest...,
  
• Ted Monohon,
  Chief Accounting Officer & VP
• June Bray,
  Director